Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Phase II Randomized Study of Interleukin-2 with or without 13-cis Retinoic Acid as Maintenance Therapy in Patients with Advanced Cancer Responsive to Chemotherapy

FRANCESCO RECCHIA, GAETANO SAGGIO, ALISIA CESTA, EDOARDO ALESSE, RITA GALLO, STEFANO NECOZIONE and SILVIO REA
Anticancer Research July 2005, 25 (4) 3149-3157;
FRANCESCO RECCHIA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: frecchia1946@libero.it
GAETANO SAGGIO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALISIA CESTA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EDOARDO ALESSE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RITA GALLO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEFANO NECOZIONE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SILVIO REA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Aim: In a previous phase 1B study, we determined the optimal biological dose of interleukin-2 (IL-2) and 13-cis retinoic acid (RA), given as maintenance therapy to patients with a variety of solid tumors, responding to chemotherapy, with a high risk of relapse. This therapy produced a statistically significant increase of the CD4+/CD8+ ratio, natural killer (NK) and lymphocyte cell counts and a decrease of vascular endothelial growth factor (VEGF). The aim of this phase II randomized study was to verify the role of RA in this drug combination. Patients and Methods: One hundred and twelve patients, with locally advanced or metastatic tumors responding to chemotherapy, were randomized to receive IL-2, 1.8×106 I.U. for 5 days/week for 2 consecutive cycles of 3 weeks, with a 1-week interval (arm A), or the same regimen plus oral RA, 0.5 mg/Kg (arm B). VEGF, the CD4+/CD8+ ratio, NK and tumor markers were assessed every 2 months and response every 4 months. Results: The baseline characteristics were well balanced between the two treatment arms for age, performance status, type of disease, amount of previous chemotherapy and baseline values of NK, CD4+/CD8+ and VEGF. Toxicity was minor in both arms. After a median follow-up of 42 months, all immunological parameters improved in both arms with respect to the baseline values; this improvement was statistically more significant in arm B. There was no statistically significant difference in progression-free and in overall survival between the two arms. Conclusion: These data show that low-dose IL-2 and oral RA is more effective than IL-2 alone in improving all known prognostically significant parameters in a variety of solid tumors, including an increase of lymphocytes and a decrease of VEGF.

  • Maintenance therapy
  • IL-2
  • 13-cis retinoic acid
  • solid tumors

Footnotes

  • ↵* Presented in part at the 7th International Conference of Anticancer Research, 25-30 October 2004, Corfu, Greece.

  • Received January 11, 2005.
  • Accepted May 6, 2005.
  • Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 25 (4)
Anticancer Research
Vol. 25, Issue 4
1 Jul 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Phase II Randomized Study of Interleukin-2 with or without 13-cis Retinoic Acid as Maintenance Therapy in Patients with Advanced Cancer Responsive to Chemotherapy
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Phase II Randomized Study of Interleukin-2 with or without 13-cis Retinoic Acid as Maintenance Therapy in Patients with Advanced Cancer Responsive to Chemotherapy
FRANCESCO RECCHIA, GAETANO SAGGIO, ALISIA CESTA, EDOARDO ALESSE, RITA GALLO, STEFANO NECOZIONE, SILVIO REA
Anticancer Research Jul 2005, 25 (4) 3149-3157;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Phase II Randomized Study of Interleukin-2 with or without 13-cis Retinoic Acid as Maintenance Therapy in Patients with Advanced Cancer Responsive to Chemotherapy
FRANCESCO RECCHIA, GAETANO SAGGIO, ALISIA CESTA, EDOARDO ALESSE, RITA GALLO, STEFANO NECOZIONE, SILVIO REA
Anticancer Research Jul 2005, 25 (4) 3149-3157;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Impact of Surgery Refusal on Overall Survival in Merkel Cell Carcinoma
  • Association of County-level Social Determinants and Pancreatic Cancer Incidence in the United States
  • Efficacy and Treatment Outcomes of First-line Pazopanib Therapy in Advanced Renal Cell Carcinoma in Greece
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire